Theotokoglou Sofia, Sgouros Dimitrios, Theodoropoulos Konstantinos, Syrmali Anna, Polyderas George, Katoulis Alexander C
Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Athens, Greece.
Indian J Dermatol. 2021 Nov-Dec;66(6):706. doi: 10.4103/ijd.ijd_37_21.
Basal cell carcinoma (BCC) is the most frequent histological type of cancer in the world and accounts for approximately 80% of all skin cancers. In the majority of cases, they are slow-growing, low metastatic potential tumors, easy to cure by surgical or nonsurgical procedures. Giant BCC (GBCC) is a rare variant of BCC and according to the American Joint Committee on Cancer, this includes lesions with a diameter larger than 5 cm. GBCC's incidence has been reported to be less than 1%, and it displays a more aggressive behavior with both local invasion and higher metastatic potential. Archodaki . specifically reported that metastasis was present in 17.6% of GBCC patients during the primary examination. Patients with GBCC who are not suitable for either surgery or radiotherapy since 2012 seem to have another therapeutic option. Vismodegib is an oral small-molecule inhibitor of the Hedgehog pathway (HPI) that was approved for treating metastatic or locally advanced BCC in patients who are poor candidates for surgery or radiotherapy. In this case, we present a woman with two simultaneous facial GBCCs who was treated successfully using vismodegib as a monotherapy.
基底细胞癌（BCC）是全球最常见的组织学类型癌症，约占所有皮肤癌的80%。在大多数情况下，它们是生长缓慢、转移潜能低的肿瘤，通过手术或非手术方法易于治愈。巨大基底细胞癌（GBCC）是基底细胞癌的一种罕见变体，根据美国癌症联合委员会的定义，这包括直径大于5厘米的病变。据报道，GBCC的发病率低于1%，并且表现出更具侵袭性的行为，包括局部侵袭和更高的转移潜能。阿乔达基等人特别报道，在初次检查时，17.6%的GBCC患者存在转移。自2012年以来，对于不适合手术或放疗的GBCC患者似乎有了另一种治疗选择。维莫德吉是一种口服的Hedgehog信号通路（HPI）小分子抑制剂，被批准用于治疗手术或放疗效果不佳的转移性或局部晚期基底细胞癌患者。在此，我们报告一名患有两个同时发生的面部GBCC的女性患者，使用维莫德吉单药治疗获得成功。
